A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2017
At a glance
- Drugs SY 1365 (Primary)
- Indications Advanced breast cancer; Ovarian cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Syros Pharmaceuticals
- 09 Aug 2017 According to a Syros Pharmaceuticals media release, compnay expects to report preliminary clinical data in 2018.
- 15 May 2017 According to a Syros Pharmaceuticals media release, the first patient has been dosed in this trial. Anthony W. Tolcher is an investigator of this trial.
- 02 May 2017 Status changed from not yet recruiting to recruiting.